ClinicalTrials.gg
CompletedNCT01902251Updated Sep 9, 2014

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

A Phase 1 interventional study of Enzalutamide tablet and Enzalutamide capsule in Prostate Cancer and Pharmacokinetics of Enzalutamide, sponsored by Astellas Pharma Europe B.V.. Completed at 4 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-09.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
94th of 125
27 · median 52
Started
2012
with 4 others
Phase 1
22 of 125
2 open now
Registered
15th of 125
by date
Lead sponsor
6 of 125
Astellas Pharma Europe B.V.

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 94th largest by enrollment, is one of 5 that started in 2012, is one of 22 in phase 1, and was the 15th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A multiple dose relative bioavailability study in patients with prostate cancer comparing a capsule and a tablet formulation of enzalutamide.

03

Conditions studied

  • Prostate Cancer
  • Pharmacokinetics of Enzalutamide

Browse trials for

Keywords

  • Phase 1
  • Prostate cancer
  • Bioavailability
  • Food effect
  • Pharmacokinetics
  • Xtandi
  • Enzalutamide
  • MDV3100
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed prostate cancer (all stages) for whom androgen deprivation therapy is indicated (except when indicated in a /adjuvant setting). Subjects may be on ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., medical or surgical castration) at study entry.
  • Progressive disease by Prostate-specific antigen (PSA) or imaging. Disease progression for study entry is defined as one or more of the following 3 criteria:

    • PSA progression defined by a minimum of 2 rising PSA levels with an interval of ≥1 week between each determination. The PSA value during the pre- period should be ≥2 μg/L (2 ng/mL);
    • Soft tissue disease progression defined by the , version 1.1 (RECIST 1.1) for soft tissue disease
    • Bone disease progression defined by two or more new lesions on bone scan

Exclusion criteria

Exclusion Criteria:

  • Treatment with chemotherapy within 4 weeks prior to enrollment (Day 1 visit) or plans to initiate treatment with chemotherapy during the study.
  • History of seizure or any condition that may predispose to seizure. Also, history of loss of consciousness, or within 12 months prior to enrollment (Day 1 visit).
  • Patients who previously received treatment with Enzalutamide.
  • Concomitant use of drugs that are potent inducers and/or inhibitors of and CYP2C8.
  • Confirmed CYP2C8 poor metabolizer status based on genotyping analysis.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Enzalutamide tablet

    Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks

    Drug: Enzalutamide tablet

  • Active comparator
    Enzalutamide capsule

    Multiple once daily oral doses of enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks

    Drug: Enzalutamide capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic profile of Enzalutamide under fasted conditions measured by Cmax (Maximum concentration)

    Day 56 (fasted) Cmax under steady state conditions of enzalutamide

    Time frame: Day1 through Day 56 (12 samples)

  2. Pharmacokinetic profile of Enzalutamide under fasted conditions measured by AUC0-24h (Area under the concentration-time curve 0-24h)

    Day 56 (fasted) AUC0-24h under steady state conditions of enzalutamide

    Time frame: Day1 through Day 56 (12 samples)

Secondary outcomes

  1. Pharmacokinetic profile of Enzalutamide under fasted and fed conditions

    Measured by: Cmax, tmax (Time to attain Cmax), AUC0-24h, Ctrough (Trough concentration), PTR (Peak-trough ratio), CLss/F (Apparent clearance at steady state)

    Time frame: Day 1, 8, 29, 55, 56 and 57 (38 samples)

  2. Pharmacokinetic profile of MDPC0001 alone, MDPC0002 alone and sum of Enzalutamide plus MDPC0002

    Measured by: Ctrough, Cmax, tmax, AUC0-24h, Ctrough (24h after dosing), PTR

    Time frame: Day 8, 29, 55, 56 and 57 (26 samples)

  3. Evaluation of the safety and tolerability of two oral formulations of Enzalutamide assessed through vital signs, adverse events, electrocardiogram and clinical laboratory assessments

    Time frame: Day 1 through Day 58

07

Study locations

4 sites
  • University of Colorado - Anschutz Medical Campus
    Denver, Colorado 80045, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • South Texas Accelerated Research Therapeutics
    San Antonio, Texas 78229, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2013
First posted
Jul 18, 2013
Start
Nov 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Last update
Sep 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01902251
Collaborators
Medivation, Inc.
Responsible party
Sponsor
First posted
Jul 18, 2013
Start date
Nov 2012
Primary completion
Oct 2013
Completion
Oct 2013
Last update
Sep 9, 2014

Study contacts

Clinical Study Manager
study director · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion